Quoin Pharmaceuticals, Ltd.
QNRX
$6.97
-$0.18-2.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.71M | 6.60M | 6.49M | 6.42M | 6.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.15M | 17.46M | 16.29M | 14.18M | 12.68M |
| Operating Income | -19.15M | -17.46M | -16.29M | -14.18M | -12.68M |
| Income Before Tax | -18.67M | -16.99M | -15.80M | -13.77M | -12.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.67 | -16.99 | -15.80 | -13.77 | -12.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.67M | -16.99M | -15.80M | -13.77M | -12.17M |
| EBIT | -19.15M | -17.46M | -16.29M | -14.18M | -12.68M |
| EBITDA | -19.05M | -17.36M | -16.19M | -14.08M | -12.58M |
| EPS Basic | -424.11 | -577.69 | -743.46 | -1.14K | -1.47K |
| Normalized Basic EPS | -7.57 | -10.32 | -13.28 | -20.30 | -26.28 |
| EPS Diluted | -424.36 | -578.51 | -749.47 | -1.14K | -1.48K |
| Normalized Diluted EPS | -7.57 | -10.32 | -13.28 | -20.30 | -26.28 |
| Average Basic Shares Outstanding | 8.75M | 6.50M | 4.26M | 1.94M | 1.50M |
| Average Diluted Shares Outstanding | 249.70K | 185.60K | 121.50K | 55.30K | 42.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |